Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial

Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; John Camm; Tobias Derfuss; Bernd C Kieseier; Till Sprenger; Kristin Greenough; Pingping Ni; Tomohiko Harada

doi:10.1016/s1474-4422(16)30192-2

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(16)30192-2 ◽

2016 ◽

Vol 15 (11) ◽

pp. 1148-1159 ◽

Cited By ~ 28

Author(s):

Ludwig Kappos ◽

Douglas L Arnold ◽

Amit Bar-Or ◽

John Camm ◽

Tobias Derfuss ◽

...

Keyword(s):

Multiple Sclerosis ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Relapsing Multiple Sclerosis

Download Full-text

Faculty Opinions recommendation of Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726657561.793522432 ◽

2016 ◽

Author(s):

Jeremy Chataway ◽

Anisha Doshi

Keyword(s):

Multiple Sclerosis ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Relapsing Multiple Sclerosis

Download Full-text

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(14)70209-1 ◽

2014 ◽

Vol 13 (11) ◽

pp. 1100-1107 ◽

Cited By ~ 225

Author(s):

David W Dodick ◽

Peter J Goadsby ◽

Stephen D Silberstein ◽

Richard B Lipton ◽

Jes Olesen ◽

...

Keyword(s):

Episodic Migraine ◽

Calcitonin Gene Related Peptide ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Related Peptide ◽

Phase 2 Trial ◽

Calcitonin Gene

Download Full-text

SAT0575 Safety and efficacy of lutikizumab (ABT-981), an anti–interleukin-1 alpha/beta dual variable domain (DVD) immunoglobulin, in subjects with knee osteoarthritis: results from the randomised, double-blind, placebo-controlled, parallel-group phase 2 trial

10.1136/annrheumdis-2018-eular.2727 ◽

2018 ◽

Author(s):

R. Fleischmann ◽

H. Bliddal ◽

F. Blanco ◽

T. Schnitzer ◽

C. Peterfy ◽

...

Keyword(s):

Knee Osteoarthritis ◽

Interleukin 1 ◽

Dual Variable ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Parallel Group ◽

Alpha Beta

Download Full-text

Faculty Opinions recommendation of Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.720592850.793525445 ◽

2016 ◽

Author(s):

Mark Obermann ◽

Dagny Holle

Keyword(s):

Episodic Migraine ◽

Calcitonin Gene Related Peptide ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Related Peptide ◽

Phase 2 Trial ◽

Calcitonin Gene

Download Full-text

Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(16)30196-x ◽

2016 ◽

Vol 15 (11) ◽

pp. 1160-1169 ◽

Cited By ~ 99

Author(s):

Kevin N Sheth ◽

Jordan J Elm ◽

Bradley J Molyneaux ◽

Holly Hinson ◽

Lauren A Beslow ◽

...

Keyword(s):

Phase 2 ◽

Brain Swelling ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Hemispheric Infarction

Download Full-text

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(19)30137-1 ◽

2019 ◽

Vol 18 (9) ◽

pp. 845-856 ◽

Cited By ~ 24

Author(s):

Diego Cadavid ◽

Michelle Mellion ◽

Raymond Hupperts ◽

Keith R Edwards ◽

Peter A Calabresi ◽

...

Keyword(s):

Multiple Sclerosis ◽

Phase 2 ◽

Safety And Efficacy ◽

Phase 2 Trial ◽

Relapsing Multiple Sclerosis

Download Full-text

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(16)00019-3 ◽

2016 ◽

Vol 15 (4) ◽

pp. 382-390 ◽

Cited By ~ 187

Author(s):

Hong Sun ◽

David W Dodick ◽

Stephen Silberstein ◽

Peter J Goadsby ◽

Uwe Reuter ◽

...

Keyword(s):

Episodic Migraine ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial

Download Full-text

Faculty Opinions recommendation of Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736170451.793566295 ◽

2019 ◽

Author(s):

Jeremy Chataway ◽

Nevin John

Keyword(s):

Multiple Sclerosis ◽

Phase 2 ◽

Safety And Efficacy ◽

Phase 2 Trial ◽

Relapsing Multiple Sclerosis

Download Full-text

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(16)30399-4 ◽

2017 ◽

Vol 16 (3) ◽

pp. 208-216 ◽

Cited By ~ 26

Author(s):

Vincent Meininger ◽

Angela Genge ◽

Leonard H van den Berg ◽

Wim Robberecht ◽

Albert Ludolph ◽

...

Keyword(s):

Amyotrophic Lateral Sclerosis ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Lateral Sclerosis

Download Full-text

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(17)30083-2 ◽

2017 ◽

Vol 16 (6) ◽

pp. 425-434 ◽

Cited By ~ 247

Author(s):

Stewart Tepper ◽

Messoud Ashina ◽

Uwe Reuter ◽

Jan L Brandes ◽

David Doležil ◽

...

Keyword(s):

Chronic Migraine ◽

Preventive Treatment ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial

Download Full-text